GWB

Advisory Board

Paul Michael Ramirez, Ph.D.

Dr. Paul Michael Ramirez is a specialist in psychometric assessments for CNS research trials. He is currently the President of CNS Ratings, LLC and is Professor of Neuroscience/Neuropsychology, Psychopathology and Psychopharmacology within the Clinical Psychology Doctoral Program at Long Island University in New York City

Dr. Ramirez has made over 200 professional presentations, and over the past 20 years, has provided rater training for assessment scales across CNS indications as well as for the assessment of cognitive disorders throughout North America, South America, Central America, Asia, Eastern and Western Europe, Scandinavia and South Africa. He was also formally co-founder and CEO of the Prophase Training Group (now doing business as ProPhase). Dr. Ramirez has published numerous papers on schizophrenia and other major mental disorders and has been Principal Investigator on grants from the National Institute of Health (NIH), National Cancer Institute (NCI), The National Institute of General Medical Sciences (NIGMS) and pharmaceutical industry sponsors.

Dr. Ramirez is also listed as a contributing author of the Positive and Negative Syndrome Scale (PANSS) and is co-author of the Informant Questionnaire for the PANSS (IQ-PANSS) and co-author of the official MHS Japanese translation of the PANSS.

Dr. Ramirez completed his doctoral degree in Psychology at The City College of The City University of New York with a specialization in Clinical Neuropsychology and a sub specialization in Clinical Psychopathology. He later completed a Postdoctoral Program in Psychopharmacology at Fairleigh Dickerson University.   Dr. Ramirez also earned an M.Phil. in Psychology (Conc.: Neuropsychology) from the Graduate School & University Center, City University of New York.

 

Tom Haskins, Ph.D.

J. Thomas Haskins, Ph.D. is a pharmaceutical professional with over 25 years of research (discovery and clinical Phases I-IV) and management experience (both US and international assignments) in the neurosciences.  Tom has experience in the global clinical development of new products in the therapeutic indications of generalized anxiety disorder, panic disorder, major depressive disorder, schizophrenia (injectable antipsychotics), neuropathic pain, hypnotics, stroke and Alzheimer’s disease.  Presently Tom is an independent consultant to the pharmaceutical industry, advising clients on clinical development plan content, product differentiation strategies, and protocol design.  Earlier he was leader of new product identification and development effort for products originating both internally and externally.  Previously, Tom lead matrix style teams for multiple pipeline assets and was responsible for development of these molecules from the bench through the end of Phase 2a (GMP, GLP, GCP, regulatory interactions, biomarker development, etc.).  This extensive experience in managing and optimizing research teams, implementing productive research and product differentiation strategies, interfacing with marketing and executive management and highly effective alliance management has resulted in his wide recognition for integrity, diligence, dependability and expertise.  Tom is also widely recognized by key opinion leaders and academic institutions for effective and productive sponsor/investigator relationships.

Bill Troetel, Pharm. D. 

William M. Troetel, Ph.D., has spent almost forty years in the field of Regulatory Affairs having held positions in the FDA, industry and primarily as a consultant.  He has been personally involved in the filing of numerous INDs and NDAs.  At present, Dr. Troetel provides regulatory consultations and support to U.S., European and Japanese pharmaceutical and biotech companies on the development and preparation of INDs, NDAs, supplemental NDAs and DMFs, as well as offering advice and strategic planning for drug development programs and participating in interactions with FDA.

Dr. Troetel has done a great deal of teaching and public speaking in the area of Regulatory Affairs, especially on the topic of the format and content of the IND and the NDA, FDA strategic planning and orphan drugs, as well as teaching courses concerning Good Clinical Practices.  He served as Course Director for the Center for Professional Advancement teaching the IND/NDA course in the United States and Europe for more than twenty-five years.

Dr. Troetel holds a B. S. degree in Pharmacy from the Columbia University College of Pharmacy, New York, NY; an M.S. degree in Pharmaceutical Chemistry from the Temple University School of Pharmacy in Philadelphia, PA; and a Ph.D. in Pharmacology from the Thomas Jefferson University, Jefferson Medical College, also in Philadelphia.

 

Ralph Lilore, Esq.

Ralph T. Lilore, a graduate of Yale University and Seton Hall Law School, is a private-practice attorney with over forty years of private and corporate legal practice specializing in Intellectual Property law in the medical, pharmaceutical, diagnostics and healthcare fields. He has been deeply involved in the legal and business aspects of numerous complex transactions including product licensing, technology transfer, regulatory and clinical affairs and related transactions. Specific technical areas of activity include biotechnology, organic chemistry, genetic engineering, biology and immunology.

Prior to private practice, he was Vice President of Corporate Development and Member of the Board of Directors of Ortho Diagnostic Systems, Inc. a subsidiary of Johnson & Johnson, where he directed staff in the identification, evaluation, and negotiation of licenses, mergers, and acquisitions of companies, products, processes, patents, and know-how in the pharmaceutical, immunological, biological, and diagnostics fields.  Earlier he served as Attorney in the Johnson & Johnson Office of General Counsel, with responsibilities for negotiation of licenses, patent activities and various contract matters for Ortho Diagnostic Systems, Inc. and Ortho Pharmaceuticals, Inc.

 

Paul E. Thievon

Paul E. Thievon is the Founder of Thievon Horticultural Products and currently serves as the Managing Partner and President.  After receiving a Bachelor’s of Science degree in Ornamental Horticulture from Delaware Valley College in PA he worked for Garden State Florist in Warren, NJ.  After two years of experience working with Garden State and gaining knowledge around growing horticultural products and selling them in the retail space, he left to join McHutchison Horticultural Distributors, a division of Sandoz.  Paul was responsible for wholesale sales in central and southern NJ where he rapidly became one of the company’s most successful members of the sales team.

In 2006, Paul founded Thievon Horticultural Products in an effort to provide his customers with better service as well as better products.  He is one of the youngest entrepreneurs in this business and realized his vision within the first year of the company’s formation.  The company prides itself on providing some of the best horticultural products from around the country and ships from the growers dock directly to the customer’s door.  Paul has and is responsible for the daily operations, financial aspects and managing the sales team.

 

John S. Thievon

John S. Thievon is the President of Dey Pharma, LP, a division of Mylan, Inc. Mr. Thievon has more than 20 years of professional experience in strategic product launches, marketing, commercialization, sales penetration and distribution leadership.   After earning a Bachelor of Business Administration degree in Marketing from Pace University, Mr. Thievon began his career in the pharmaceutical industry as a pharmaceutical sales representative for Ortho-McNeil, a division of Johnson & Johnson.  He moved on to join IMS Health and then Adams Respiratory Therapeutics where he held positions as Executive Vice President of Commercial Operations and Executive Vice President of Sales, Marketing and Business Development over a nine-year span.

Mr. Thievon is widely recognized for building the Adams’ marketing platform and leading the launch of Mucinex™. Integral to success of Mucinex™ was Mr. Thievon’s leadership in the design of the award-winning TV campaigns, setting the stage for a new market niche, and winning industry/consumer product approval as a #1 Physician/Pharmacist-Recommended over-the-counter medication.  After the successful sale of Adams to Reckitt Benckiser, Mr. Thievon was appointed President and CEO of Middlebrook Pharmaceuticals where he built the company into a 450-person organization before its assets were acquired by Victory Pharma.

Your Name *

Your Email *

Your Title *

Company *

Your Message